This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
"A Fighter From the Ground Up." Popular Science, July 1943, one of earliest detailed articles on P-51A Archived 23 October 2013 at the Wayback Machine "Wild Horses of the Sky," Popular Mechanics, November 1943 Joe Baugher, North American P-51 Mustang Archived 23 July 2011 at the Wayback Machine Camouflage and Markings of P-51 Mustang Parts 1–4 USAAF plus Allison engine versions RAF and Commonwealth Archived 1 March 2012 at the Wayback Machine Allison-powered Mustang performance test reports; 1940, 1942, 1943, 1944 Archived 22 December 2008 at the Wayback Machine P-51B Mustang performance test report, May 1943 Archived 9 January 2008 at the Wayback Machine P-51 combat reports Archived 23 December 2007 at the Wayback Machine NACA-WR-L-566 "Flying qualities and stalling characteristics of North American XP-51 airplane", April 1943. (PDF) North American P-51 profile, photos and technical details for each mk "Flight Characteristics of the North American P-51 Mustang: How to Fly the P-51 Mustang" on YouTube "Mustang Squadron" a 1942 Flight article "Army Co-Op Mustang" a 1942 Flight article "Unobtrusive Cleverness" a 1942 Flight article "Long Range Mustang" a 1944 Flight article P-51 in Flight Over California (1942) Flight manual Mustang P-51A Archived 15 May 2024 at the Wayback Machine – The Museum of Flight Digital Collections Pilot training manual for the Mustang P-51 Archived 8 October 2024 at the Wayback Machine – The Museum of Flight Digital Collections
== Awards == 2009: BBSRC David Phillips Fellowship 2012: ERC Starting Grant 2014: Talented Young Italians Award (Research and Innovation) 2015: EFMC Prize for Young Medicinal Chemist in Academia 2015: ICBS Young Chemical Biologist Award 2016: RSC Capps Green Zomaya Award 2016: MedChemComm Emerging Investigator Lectureship 2016: Fellow of the Royal Society of Chemistry (FRSC) 2022: Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery 2023: Fellow of the Royal Society of Edinburgh (FRSE) 2025: Fellow of the Royal Society 2026: Fellow of the Academy of Medical Sciences (FMedSci)
List of hot beverages Tea culture Health effects of tea Tincture, the often more concentrated plant extracts made in pure grain alcohol, glycerin, or vinegar Yerba mate Hot chocolate Coffee substitute Tea in France Chinese sweet tea
=== Generating single stranded oligonucleotide library === The first step of SELEX involves the synthesis of fully or partially randomized oligonucleotide sequences of some length flanked by defined regions which allow PCR amplification of those randomized regions and, in the case of RNA SELEX, in vitro transcription of the randomized sequence. While Ellington and Szostak demonstrated that chemical synthesis is capable of generating ~1015 unique sequences for oligonucleotide libraries in their 1990 paper on in vitro selection, they found that amplification of these synthesized oligonucleotides led to significant loss of pool diversity due to PCR bias and defects in synthesized fragments. The oligonucleotide pool is amplified and a sufficient amount of the initial library is added to the reaction so that there are numerous copies of each individual sequence to minimize the loss of potential binding sequences due to stochastic events. Before the library is introduced to target for incubation and selective retention, the sequence library must be converted to single stranded oligonucleotides to achieve structural conformations with target binding properties.
=== Housing === Moore has described himself as a "YIMBY". He supports the right to counsel in eviction cases, saying that providing tenants with access to counsel is "the just thing to do and it is the right thing to do". On his campaign website, Moore says he would address the "unfair appraisal values in historically redlined neighborhoods" and provide increased funding for the Maryland Department of Housing and Community Development. During a town hall in August 2023, Moore suggested that nonprofits could be used to help lower housing costs in addition to increasing the state's affordable housing inventory and supporting current homeowners. In January 2024, Moore introduced bills to increase federal funding and reducing barriers for affordable housing projects in the state, especially those around commuter rail stations, as well as legislation establishing a "Tenant's Bill of Rights" and providing additional protections to renters against evictions. While Moore's tenant protections bills passed the legislature unchanged, legislators opted to weaken the Housing Expansion and Affordability Act by removing provisions that would block jurisdictions from using an adequate public facilities ordinance to block the construction of affordable housing and modifying the qualifications needed for affordable housing projects to be eligible for density bonuses. In October 2024, Moore signed an executive order aimed at removing 5,000 of Baltimore's 13,000 vacant homes within five years.
Sources: en.wikipedia.org
=== Lifestyle and diet === Drinking enough water may help to keep skin hydrated, especially in individuals who are chronically dehydrated. A poor diet lacking vitamins can lead to skin problems, such as scurvy, pellagra, and numerous subclinical skin pathologies that have not been studied in detail. Lack of sleep has been shown to make conditions like atopic dermatitis, eczema and psoriasis worse, and these conditions have in turn been shown to reduce sleep quality.
Tim Hortons, currently owned by Restaurant Brands International, opened its first store on May 17, 1964, in Hamilton, Ontario. It is the fourth largest publicly traded quick-service restaurant chain in North America based on market capitalization, and the largest in Canada. It has cornered the Canadian market for baked goods (76%) and coffee (62% compared to Starbucks, in the number two position, at 7%). The company has experienced substantial growth in the United States, where it has 613 stores (April 2011, about 220 more than it had in June 2008). It has a same-store sales growth rate of 3.9% in Canada and 4.9% in the US. The new partnership with Cold Stone Creamery helped push its US presence to over 600 stores. The partnership has since dissolved. Sales exceeded $2 billion in 2008. It was controlled by Wendy's International Inc. for 11 of the 46 years of operation, from August 8, 1995, until the end of 2006. On April 3, 2011, Tim Hortons oversaw 3,782 locations in North America 3,169 of which were in Canada. In the fourth quarter of 2010 Tim Hortons' profits were 27% more than they were over the entire 2009 fiscal year (for the quarter net income was up 314%). In Forbes' 2011 edition of the world's 2000 largest companies, Tim Hortons placed 1469th overall (up from 1714th in 2010) with annual sales of $2.6 billion (up from $2.014 billion in 2010), profits totalling $628 million (up from $280 million), assets worth $2.5 billion (up from $1.90 billion) and a market value of $7.5 billion (up from $5.41 billion).
According to the World Database on Protected Areas, 37% of Belize's land territory falls under some form of official protection, giving Belize one of the most extensive systems of terrestrial protected areas in the Americas. By contrast, Costa Rica only has 27% of its land territory protected. Around 20.4% of Belize's marine and coastal areas, which contain the Belize Barrier Reef, are protected. The Belize Barrier Reef is a UNESCO-recognized World Heritage Site and is the second-largest barrier reef in the world, behind Australia's Great Barrier Reef. A remote sensing study conducted by the Water Center for the Humid Tropics of Latin America and the Caribbean (CATHALAC) and NASA, in collaboration with the Forest Department and the Land Information Centre (LIC) of the government of Belize's Ministry of Natural Resources and the Environment (MNRE), and published in August 2010 revealed that Belize's forest cover in early 2010 was approximately 62.7%, down from 75.9% in late 1980. A similar study by Belize Tropical Forest Studies and Conservation International revealed similar trends in terms of Belize's forest cover. Both studies indicate that each year, 0.6% of Belize's forest cover is lost, translating to the clearing of an average of 10,050 hectares (24,835 acres) each year. The USAID-supported SERVIR study by CATHALAC, NASA, and the MNRE also showed that Belize's protected areas have been extremely effective in protecting the country's forests.
Physical examination of the back should assess for posture and deformities. Pain elicited by palpating certain structures may be helpful in localizing the affected area. A neurologic exam is needed to assess for changes in gait, sensation and motor function. Determining if there are radicular symptoms, such as pain, numbness or weakness that radiate down limbs, is important for differentiating between central and peripheral causes of back pain. The straight leg test is a maneuver used to determine the presence of lumbosacral radiculopathy, which occurs when there is irritation in the nerve root that causes neurologic symptoms such as numbness and tingling. Non-radicular back pain is most commonly caused by injury to the spinal muscles or ligaments, degenerative spinal disease or a herniated disc. Disc herniation and foraminal stenosis are the most common causes of radiculopathy. Imaging of the spine and laboratory tests is not recommended during the acute phase. This assumes that there is no reason to expect that the patient has an underlying problem. In most cases, the pain subsides naturally after several weeks. People who seek diagnosis through imaging are typically less likely to receive a better outcome than are those who wait for the condition to resolve.
=== Chemiluminescence === This technology is based on the luminescence of specific compounds when they bind to explosive particles. Its sensitivity can reach the nanogram (ppb) level. It can be applied in non-electronic formats, such as sprays and test papers, as well as in electronic devices.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.